Ritter Pharmaceuticals, Inc. (RTTR) financial statements (2021 and earlier)

Company profile

Business Address 2042 CORTE DEL NOGAL
CALIFORNIA, CA 92011
State of Incorp. DE
Fiscal Year End March 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2020
Q2
6/30/2020
Q1
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:14262248
Cash and cash equivalents14262246
Short-term investments      3
Other undisclosed cash, cash equivalents, and short-term investments      0
Receivables00 0000
Inventory, net of allowances, customer advances and progress billings11     
Inventory11     
Prepaid expense2   100
Other undisclosed current assets0201  (0)
Total current assets:18662359
Noncurrent Assets
Operating lease, right-of-use asset0100000
Property, plant and equipment2200000
Intangible assets, net (including goodwill)11     
Intangible assets, net (excluding goodwill)11     
Other noncurrent assets0000000
Other undisclosed noncurrent assets00     
Total noncurrent assets:3311000
TOTAL ASSETS:21973359
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1222334
Accounts payable0111322
Accrued liabilities1100002
Deferred revenue00     
Debt11 0000
Due to related parties01     
Other undisclosed current liabilities21170    
Total current liabilities:232122334
Noncurrent Liabilities
Long-term debt and lease obligation01  000
Long-term debt, excluding current maturities00     
Operating lease, liability00  000
Liabilities, other than long-term debt00     
Deferred revenue00     
Total noncurrent liabilities:01  000
Total liabilities:242222334
Stockholders' equity
Stockholders' equity attributable to parent, including:(3)(13)51025
Common stock0000000
Additional paid in capital71538780767575
Accumulated other comprehensive income      0
Accumulated deficit(74)(66)(82)(80)(80)(78)(75)
Other undisclosed stockholders' equity attributable to parent0002455
Total stockholders' equity:(3)(13)51025
TOTAL LIABILITIES AND EQUITY:21973359

Income statement (P&L) ($ in millions)

9/30/2020
Q2
6/30/2020
Q1
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
Revenues11     
Cost of revenue
(Cost of Goods and Services Sold)
 (0)     
Gross profit:11     
Operating expenses(5)(3)(2)(1)(2)(3)(5)
Other undisclosed operating income 0     
Operating loss:(4)(3)(2)(1)(2)(3)(5)
Nonoperating income (expense)(4)1611000
Interest and debt expense(0)(0)     
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes0(32)     
Loss from continuing operations before income taxes:(8)(19)(2)(0)(2)(3)(5)
Income tax expense(0)(0)     
Net loss available to common stockholders, diluted:(8)(19)(2)(0)(2)(3)(5)

Comprehensive Income ($ in millions)

9/30/2020
Q2
6/30/2020
Q1
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
Net loss:(8)(19)(2)(0)(2)(3)(5)
Other undisclosed comprehensive income (loss)     (0)0
Comprehensive loss, net of tax, attributable to parent:(8)(19)(2)(0)(2)(3)(5)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: